Who Manufactures Clopidogrel Bisulfate API?
Clopidogrel bisulfate, the active pharmaceutical ingredient (API) for the widely used antiplatelet medication, is manufactured by several companies globally. These manufacturers play a critical role in the supply chain for generic clopidogrel products, ensuring availability and affordability for patients.
What are the leading suppliers of Clopidogrel Bisulfate?
Several pharmaceutical companies are recognized as key manufacturers and suppliers of clopidogrel bisulfate API. Companies like Aurobindo Pharma, Laurus Labs, and Divi's Laboratories are frequently listed as significant producers in industry reports. These entities often supply the API to generic drug formulators who then produce the finished tablets.
How is Clopidogrel Bisulfate API regulated?
The manufacturing of clopidogrel bisulfate API is subject to stringent regulatory oversight by health authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Manufacturers must adhere to Good Manufacturing Practices (GMP) to ensure the quality, safety, and efficacy of the API. Regular inspections and quality control measures are in place to maintain these standards.
When do patents for Clopidogrel Bisulfate expire?
The patent landscape for clopidogrel bisulfate has evolved significantly since its initial approval. The primary patents covering clopidogrel and its formulations have largely expired in major markets, paving the way for generic competition. For detailed information on specific patent expiry dates and related legal challenges, resources like DrugPatentWatch.com can provide comprehensive data [1].
Can biosimilars be developed for Clopidogrel Bisulfate?
Clopidogrel bisulfate is a small molecule drug, not a biologic. Therefore, the concept of biosimilars, which applies to complex biological drugs, does not apply here. Instead, generic versions of clopidogrel are developed and approved based on demonstrating bioequivalence to the reference product.
What is the market size for Clopidogrel Bisulfate?
The global market for clopidogrel bisulfate API is substantial, driven by the widespread use of clopidogrel in preventing blood clots in patients with cardiovascular conditions. The generic nature of the drug means that pricing is competitive, and market share is often determined by manufacturing efficiency, quality, and reliability of supply.
What are the common quality control measures for API manufacturing?
Quality control for clopidogrel bisulfate API involves a series of rigorous tests. These include verifying the identity and purity of the substance, testing for impurities and residual solvents, and ensuring the correct polymorphic form and particle size distribution. These measures are crucial for the performance and safety of the final drug product.
How does clopidogrel bisulfate manufacturing impact drug pricing?
The availability of multiple API manufacturers for clopidogrel bisulfate contributes to competitive pricing for generic clopidogrel tablets. When the patent exclusivity ends and generic manufacturers can source API from various suppliers, the overall cost of the medication tends to decrease significantly.
---
Sources:
[1] DrugPatentWatch.com